INTRODUCTION: SPECIAL ISSUE ON AGENCY AND RATIONALITY by SERGIO TENENBAUM, DAVID HORST

Get full text

Pathology of Combined Hepatocellular Carcinoma-Cholangiocarcinoma: An Update by Florian Roßner, Bruno Valentin Sinn, David Horst

Get full text

Pan-cancer EMT-signature identifies RBM47 down-regulation during colorectal cancer progression by Matjaz Rokavec, Markus Kaller, David Horst, Heiko Hermeking

Get full text

Characterization of a p53/miR-34a/CSF1R/STAT3 Feedback Loop in Colorectal CancerSummary by Xiaolong Shi, Markus Kaller, Matjaz Rokavec, Thomas Kirchner, David Horst, Heiko Hermeking

Get full text

The Relationship between the M1/M2 Macrophage Polarization and the Degree of Ossicular Erosion in Human Acquired Cholesteatoma: An Immunohistochemical Study by Mohamed Bassiouni, Philipp Arens, Samira Ira Zabaneh, Heidi Olze, David Horst, Florian Roßner

Get full text

Quantitative protein biomarker panels: a path to improved clinical practice through proteomics by Johannes Hartl, Florian Kurth, Kai Kappert, David Horst, Michael Mülleder, Gunther Hartmann, Markus Ralser

Get full text

Multicolor lineage tracing reveals clonal architecture and dynamics in colon cancer by Sebastian Lamprecht, Eva Marina Schmidt, Cristina Blaj, Heiko Hermeking, Andreas Jung, Thomas Kirchner, David Horst

Get full text

Tumor budding outperforms ypT and ypN classification in predicting outcome of rectal cancer after neoadjuvant chemoradiotherapy by Iryna Trotsyuk, Halina Sparschuh, Alice Josephine Müller, Konrad Neumann, Martin Kruschewski, David Horst, Sefer Elezkurtaj

Get full text

Targeting non-coding RNAs to overcome cancer therapy resistance by BaoQing Chen, Mihnea P. Dragomir, Chen Yang, Qiaoqiao Li, David Horst, George A. Calin

Get full text

Ex vivo tissue slice culture system to measure drug-response rates of hepatic metastatic colorectal cancer by Steve Z. Martin, Daniel C. Wagner, Nina Hörner, David Horst, Hauke Lang, Katrin E. Tagscherer, Wilfried Roth

Get full text

Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis by Baoqing Chen, Chen Yang, Mihnea P. Dragomir, Dongmei Chi, Wenyan Chen, David Horst, George A. Calin, Qiaoqiao Li

Get full text

Teacher-student collaborated multiple instance learning for pan-cancer PDL1 expression prediction from histopathology slides by Darui Jin, Shangying Liang, Artem Shmatko, Alexander Arnold, David Horst, Thomas G. P. Grünewald, Moritz Gerstung, Xiangzhi Bai

Get full text

Colorectal cancers mimic structural organization of normal colonic crypts. by Laura Cernat, Cristina Blaj, Rene Jackstadt, Lydia Brandl, Jutta Engel, Heiko Hermeking, Andreas Jung, Thomas Kirchner, David Horst

Get full text

Ap4 is rate limiting for intestinal tumor formation by controlling the homeostasis of intestinal stem cells by Stephanie Jaeckel, Markus Kaller, Rene Jackstadt, Ursula Götz, Susanna Müller, Sophie Boos, David Horst, Peter Jung, Heiko Hermeking

Get full text

Clinical Evidence on the Interaction Between MLK4, KRAS and Microsatellite Instability to Determine the Prognosis of Early-Stage Colorectal Carcinoma by Lydia Brandl, David Horst, Thomas G. P. Grünewald, Julia Mayerle, Andrea Sendelhofert, Jens Neumann, Thomas Kirchner, Enrico N. De Toni

Get full text

The Immune Checkpoint Landscape in Tumor Cells of Pancreatic Ductal Adenocarcinoma by Florian N. Loch, Carsten Kamphues, Katharina Beyer, Christian Schineis, Wael Rayya, Johannes C. Lauscher, David Horst, Mihnea P. Dragomir, Simon Schallenberg

Get full text

An in-depth analysis of the mitochondrial phylogenetic landscape of Cambodia by Anita Kloss-Brandstätter, Monika Summerer, David Horst, Basil Horst, Gertraud Streiter, Julia Raschenberger, Florian Kronenberg, Torpong Sanguansermsri, Jürgen Horst, Hansi Weissensteiner

Get full text

The majority of β-catenin mutations in colorectal cancer is homozygous by Alexander Arnold, Moritz Tronser, Christine Sers, Ayel Ahadova, Volker Endris, Soulafa Mamlouk, David Horst, Markus Möbs, Philip Bischoff, Michael Kloor, Hendrik Bläker

Get full text

First effectiveness data of lenvatinib and pembrolizumab as first-line therapy in advanced anaplastic thyroid cancer: a retrospective cohort study by Dominik Soll, Philip Bischoff, Anne Frisch, Marie Jensen, Zehra Karadeniz, Martina T. Mogl, David Horst, Tobias Penzkofer, Joachim Spranger, Ulrich Keilholz, Knut Mai

Get full text

Target Selection for T-Cell Therapy in Epithelial Ovarian Cancer: Systematic Prioritization of Self-Antigens by Paul Schossig, Ebru Coskun, Ruza Arsenic, David Horst, Jalid Sehouli, Eva Bergmann, Nadine Andresen, Christian Sigler, Antonia Busse, Ulrich Keller, Sebastian Ochsenreither

Get full text